In line with these findings, the anti-CD47 antibody magrolimab was revealed to show promising results when combined with azacitidine in AML and MDS patients (58), and a phase 3 study evaluating the efficacy of magrolimab in combination with venetoclax and azacytidine has been ongoing (183). This evidence concerns the gene CD47 and acute myeloid leukemia.